Elodie Montaudon
Overview
Explore the profile of Elodie Montaudon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
457
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Komar Z, Verkaik N, Dahmani A, Montaudon E, Kanaar R, Houtsmuller A, et al.
NPJ Breast Cancer
. 2025 Feb;
11(1):17.
PMID: 39962055
Breast cancer is the most common cancer amongst women worldwide, however clinically validated chemotherapy response biomarkers that can accurately predict treatment response in patients are largely lacking. Therefore, in this...
2.
Sreekumar S, Montaudon E, Klein D, Gonzalez M, Painsec P, Derrien H, et al.
Cancers (Basel)
. 2024 Oct;
16(19).
PMID: 39409880
Background: Endocrine therapy (ET) combined with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) is the preferred first-line treatment for hormone receptor-positive (HR+)/HER2- metastatic breast cancer. Although this is beneficial, acquired resistance leads...
3.
Gazzeri S, Zubchuk N, Montaudon E, Nemati F, Huot-Marchand S, Berardi G, et al.
Life Sci Alliance
. 2024 Oct;
7(12).
PMID: 39353739
Despite initial high response rates to first-line EGFR TKI, all non-small-cell lung cancer (NSCLC) with EGFR-activating mutation will ultimately develop resistance to treatment. Identification of resistance mechanisms is critical to...
4.
Decaudin D, Nemati F, Planchon J, Seguin-Givelet A, Lefevre M, Etienne V, et al.
Cancers (Basel)
. 2024 Aug;
16(16).
PMID: 39199558
The combination of chemotherapy and targeted therapy has been validated in non-small-cell lung cancer (NSCLC) patients with mutations. We therefore investigated whether this type of combined approach could be more...
5.
Saatci O, Cetin M, Uner M, Tokat U, Chatzistamou I, Ersan P, et al.
Nat Commun
. 2023 Nov;
14(1):6997.
PMID: 37914699
Resistance to endocrine therapy and CDK4/6 inhibitors, the standard of care (SOC) in estrogen receptor-positive (ER+) breast cancer, greatly reduces patient survival. Therefore, elucidating the mechanisms of sensitivity and resistance...
6.
Lawson M, Cureton N, Ros S, Cheraghchi-Bashi A, Urosevic J, DArcy S, et al.
Cancer Res
. 2023 Sep;
83(23):3989-4004.
PMID: 37725704
Significance: Camizestrant, a next-generation oral SERD, shows promise in preclinical models of ER+ breast cancer alone and in combination with CDK4/6 and PI3K/AKT/mTOR inhibitors to address endocrine resistance, a current...
7.
El-Botty R, Morriset L, Montaudon E, Tariq Z, Schnitzler A, Bacci M, et al.
Nat Commun
. 2023 Jul;
14(1):4221.
PMID: 37452026
Resistance to endocrine treatments and CDK4/6 inhibitors is considered a near-inevitability in most patients with estrogen receptor positive breast cancers (ER + BC). By genomic and metabolomics analyses of patients'...
8.
Ter Brugge P, Moser S, Bieche I, Kristel P, Ibadioune S, Eeckhoutte A, et al.
Nat Commun
. 2023 Apr;
14(1):1958.
PMID: 37029129
The high frequency of homologous recombination deficiency (HRD) is the main rationale of testing platinum-based chemotherapy in triple-negative breast cancer (TNBC), however, the existing methods to identify HRD are controversial...
9.
El-Botty R, Vacher S, Mainguene J, Briaux A, Ibadioune S, Dahmani A, et al.
Mol Oncol
. 2023 Feb;
17(10):2017-2028.
PMID: 36852691
Triple negative breast cancers (TNBCs) represent 15-20% of all breast cancers and are associated with higher recurrence and distant metastasis rate. Standard of care for early stage TNBC is anthracyclines...
10.
Piqueret B, Montaudon E, Devienne P, Leroy C, Marangoni E, Sandoz J, et al.
Proc Biol Sci
. 2023 Jan;
290(1991):20221962.
PMID: 36695032
Early detection of cancer is critical in medical sciences, as the sooner a cancer is diagnosed, the higher are the chances of recovery. Tumour cells are characterized by specific volatile...